Skip to main content
Premium Trial:

Request an Annual Quote

NCGR Licenses KeyGene's Profiling Technology

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – KeyGene and the National Center for Genome Resources, located in San Jose, NM, have inked a non-exclusive license agreement giving NCGR rights to market and conduct sequence-based mapping projects using KeyGene's Whole Genome Profiling (WGP) technology.

NCGR will combine its sequencing and informatics capabilities with the WGP technology, which is based on generating short read sequences of pooled BAC clones produced by KeyGene's partner Amplicon Express.

Wageningen, Netherlands-based KeyGene's technology uses sequence tags to assemble BAC clones at high stringency based on shared regions containing identical sequence tags. The WGP map forms a scaffold for assembling whole genome sequence data from a range of organisms.

"Many of our de novo genome projects will benefit from the WGP platform through guiding the order and orientation of our next-generation DNA sequencing-based scaffolds," NCGR President Gregory May said in a statement.

"We believe that this agreement will give a much larger customer base access to better genome assemblies that can be used as reference genomes and to support molecular breeding activities," added KeyGene's US-based VP of Business Development Mark van Haaren.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.